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Introduction
Idiopathic pulmonary fibrosis (IPF) is a devastat-
ing, progressive, fibrotic lung disease. IPF is 
characterized by irreversible loss of lung func-
tion, ultimately resulting in most patients dying 
from respiratory failure within 3–5 years. The 
most common symptoms are dry cough, dysp-
noea and fatigue.1 Though the disease course 
may vary among patients and many patients 
experience periods of relative stability, disease 
progression and worsening of symptoms are 
inevitable for the majority of patients.2,3 The 
combination of poor prognosis, uncertainty of 
disease course and severe symptom burden heav-
ily impacts quality of life (QOL) both for patients 
and family members.1,4,5 Recently, knowledge on 
the pathogenesis of the disease has improved and 
has led to the development of two antifibrotic 
drugs that slow down disease progression as 
measured by decline in pulmonary function. 
Though these drugs are major steps forward for 
patients, IPF still remains a devastating and 
deadly disease. It is encouraging that multiple 
new compounds are currently investigated in 
clinical trials, aiming at modifying the disease 
course. The majority of these trials are focused 
on disease modification measured by physiologi-
cal parameters, such as lung function. However, 
in many patients with IPF, there is no clear cor-
relation between physiological parameters and 
patient-reported outcome measures (PROMs), 
such as health-related QOL (HRQOL) scores, 
that strive to reflect how a patient feels or func-
tions. In a relentless disease as IPF, striving to 
optimize HRQOL should complement the 
endeavour to prolong life. There is a paucity of 
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interventions that convincingly improve symp-
toms and functionality for patients with IPF. 
This review summarizes the most recent insights 
into measuring and improving QOL in patients 
with IPF and postulates an ABCDE of IPF care, 
to facilitate a systematic and comprehensive 
approach to care for patients with IPF.
Health-related quality of life in IPF patients
Health-related quality of life refers to a person’s 
satisfaction with aspects of life that may be 
affected by health.6 As clinicians, we focus pri-
marily on HRQOL since QOL is also determined 
by such aspects of life as freedom, quality of envi-
ronment and financial situation. Nevertheless, 
with a relentless disease as IPF, almost all aspects 
of life can become health-related.6 Patients with 
IPF report an impaired HRQOL.1 Symptoms as 
dyspnoea, decreased mobility and cough are often 
important determinants of HRQOL.7,8 HRQOL 
is generally assessed by patient-reported outcome 
measures.9 Often, there is a poor correlation 
between physiological assessments of disease 
severity by pulmonary function testing and 
patient-reported outcomes of HRQOL and symp-
toms.10 Drugs that may modify the disease, by 
slowing down the pace of lung function decline, 
do not convincingly improve patients’ overall 
symptoms or HRQOL.11,12 Therefore, comple-
mentary disease management strategies are 
needed to improve HRQOL.
Unmet needs of IPF patients and caregivers
Several recent initiatives have examined the needs 
of patients with IPF and their relatives.1,5,13–18 
Though identifying patient-specific needs is cru-
cial in the individual treatment relationship 
between a patient and care provider, it should be 
recognized that many basic conditions for IPF 
care are still frequently unmet. An initiative by 11 
European patient advocacy groups for pulmonary 
fibrosis identified five key themes of unmet needs: 
1) better diagnosis, 2) better access to different 
treatment forms, 3) availability of emotional sup-
port, 4) improved information resources, and 5) 
equal availability of palliative and end-of-life 
care.18 The European IPF Patients Charter was 
developed based on these outcomes (http://www.
ipfcharter.org/call-to-action/).
An interesting study by Overgaard and colleagues 
not only looked at the unmet needs of patients 
with IPF, but also included family caregivers.5 
They studied patients’ and caregivers’ experiences 
of living with IPF, using extensive interviews of 
patients and their caregivers. In total, 25 patients 
and 24 family caregivers participated in the study. 
The main findings of their study showed a need 
for stepwise information and disclosure, and 
awareness of differences in reactions and wishes 
between patients and family caregivers.
A study by Russell and colleagues underscores 
the previous studies, pointing out a need for bet-
ter diagnosis of IPF, access to high-quality infor-
mation on IPF, and emotional support for both 
patients and family caregivers.19 Additionally, 
they found a need for better access to interstitial 
lung disease (ILD) specialist nurses, and high-
lighted the meaningful position of physicians and 
ILD specialist nurses as main contact persons for 
patients.
Sampson and colleagues looked at the care needs 
of IPF patients and their carers in different phases 
of disease course.17 ‘Carer’ was defined as ‘a per-
son of the patient’s choice who contributed most 
to their care or, in the early stages of disease, pro-
vided emotional support’. Their study shows that 
although patients and carers had adequate knowl-
edge of the overall prognosis of IPF, it was diffi-
cult for them to translate this knowledge regarding 
their own disease course and the corresponding 
psychological and physical treatment possibilities. 
It also recommended that patients and carers 
needed a different approach to evaluating IPF in 
clinic, and that physicians should focus not only 
on lung function parameters, but also on overall 
health status, self-management, nutrition and an 
explanation of disease progression.
An underrecognized problem, but with great 
impact on QOL, is the presence of sexual dys-
function in some patients with IPF. Erectile dys-
function has been associated with chronic 
obstructive pulmonary disease (COPD) and was 
reported to be a common problem in ILD.20,21
As a part of the US Food and Drug 
Administration’s (FDA) patient-focused drug 
development program, a meeting was conducted 
with patients to examine their perspectives in 
treatment approaches. This meeting underscored 
the need for better medication and symptom 
relief, in particular for shortness of breath, severe 
cough and fatigue.8
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Numerous other studies have evaluated the 
unmet needs of patients with IPF and their family 
caregivers.13,14,16,22 All confirm the above-men-
tioned needs, and show the importance of holistic 
complementary care, focused on optimizing QOL 
in patients with IPF and their family caregivers.
Patient-reported outcome measures
A variety of tools are used to assess the impact of 
disease on QOL in IPF; however, there is a pau-
city of specific well-validated PROMs and a lack 
of consensus on which tools to use for care and 
research.23,9 Patient-reported outcomes (PROs) 
are defined as ‘any report coming directly from 
the patient without interpretation by a third party 
about how they feel or function in relation to a 
health condition and given intervention’.24 The 
most commonly used PROMs in IPF are ques-
tionnaires originally developed to assess HRQOL 
in other chronic (respiratory) diseases. These 
questionnaires have been modified and revali-
dated for the IPF population. Two of these ques-
tionnaires, often used in IPF studies, are the Saint 
George Respiratory Questionnaire (SGRQ) and 
the Medical Outcomes Study 36-item short-form 
health survey (SF-36).25,26 Both are well validated 
and have proven to possess validity in assessing 
HRQOL in IPF.27,28 Despite these qualities, they 
have failed to convincingly show changes in 
HRQOL in the major IPF trials. The SGRQ has 
only shown some significant positive changes in 
the STEP-IPF trial (using sildenafil) and the 
INPULSIS 2 trial (using nintedanib).
Since a few years, disease-specific PROMs have 
been developed and validated in IPF patients. A 
modified IPF version of the SGRQ (SGRQ-I) was 
created by statistical analysis (Rasch analysis) of 
the SGRQ data of a clinical trial in IPF.29 The 
SGRQ-I holds validity and reliability comparable 
with the original SGRQ,29 but the experience with 
the questionnaire is limited. The King’s Brief 
Interstitial Lung Disease health status question-
naire (K-BILD) was developed in a population of 
124 patients with mixed ILD’s and 49 patients 
with IPF.10,30 The questionnaire is short (15 ques-
tions) and holds good psychometric properties. A 
Tool to Assess Quality of Life in IPF (ATAQ-
IPF) was developed in a group of 95 IPF patients.31 
The questionnaire contains 43 items and is vali-
dated in the UK and the US.32 Longitudinal stud-
ies on the performance of the K-BILD and 
ATAQ-IPF are currently underway.
In addition, regarding IPF several symptom-spe-
cific questionnaires have been used. The most 
commonly used is the University of California 
San Diego Shortness of Breath Questionnaire 
(UCSD), which assesses dyspnoea.33 One of the 
IPF trials using the USCD was the ASCEND 
trial (using pirfenidone). Though patients in this 
trial experienced a significant reduction in their 
decline of lung function, no effect in UCSD 
scores was found.11 The Medical Research 
Council dyspnoea scale was found to be predic-
tive of disease progression, but its value to assess 
response to interventions in IPF is unclear.34 The 
same limitation applies for other dyspnoea scor-
ing tools, such as the Borg Rating of Perceived 
Exertion Scale and the Baseline Dyspnoea 
Index.35,36 Though, by some estimates, over 80% 
of IPF patient’s experience cough, PROMs on 
cough in IPF are limited. Both the Leicester 
Cough Questionnaire (LCQ) and the Cough 
Quality of Life Questionnaire have been evalu-
ated in IPF, but need further longitudinal valida-
tion.37,38 Visual analogue scales (VAS) are also 
used to assess the severity, frequency and impact 
of cough.39 LCQ and cough-VAS show correla-
tion with objective cough counts.40,41 Though 
fatigue is often a problem in IPF, to our knowl-
edge no validated fatigue PROMs exist for IPF. 
Anxiety and depression are estimated to be pre-
sent in around 25% of patients with IPF and are 
important to recognize.4,42 Although no IPF spe-
cific tools exist to screen for anxiety and depres-
sion, in general practice common tools such as 
Hospital Anxiety and Depression Scale and the 
Centre for Epidemiologic Studies Depression 
Scale are often used.42,43 It is important to realize 
that though PROMs were initially mostly devel-
oped for use in clinical trials, their use is much 
broader. Using PROMs in routine care can 
improve communication, detect unrecognized 
needs and problems, and serve as outcome meas-
ures for interventions.44–46
Optimizing quality of life
Symptoms, perceptions and reactions all interact, 
and together they influence HRQOL for patients 
with IPF (Figure 1). This interacting balance wheel 
of symptoms, perception and reaction varies among 
patients, but also often changes within individual 
patients during the disease course (Figure 1).
A synchronized comprehensive management strat-
egy is vital to match patients’ needs throughout the 
Therapeutic Advances in Respiratory Disease 11(3)
160 journals.sagepub.com/home/tar
disease course.47 Below, we focus on interventions 
and treatments that may have a positive effect on 
HRQOL in IPF. To facilitate a systematic and 
comprehensive approach to IPF care, we postulate 
to use an ‘ABCDE of IPF care’ (Figure 2).
Assess patients’ needs and values
At time of diagnosis, careful discussion of prefer-
ences and needs of care should commence, allow-
ing the patient and family caregivers time and 
space to cope with the diagnosis and information 
Figure 1. Balance wheel of symptoms, perception and reaction in patients with idiopathic pulmonary fibrosis.
Figure 2. ABCDE of IPF care.
GERD, gastro-esophageal reflux disease; OSA, obstructive sleep apnoea.
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given. Not only will individual patients have dif-
ferent needs and preferences, the success of ther-
apies and interventions will also depend on 
patient factors such as expectations, experiences 
and motivations. Continuous reassessment of the 
individual patient’s wishes and the adaptation of 
interventions is crucial. Good collaboration 
between patients and health care providers is the 
foundation for good care. Both need to trust and 
respect one another. The patient is obliged to 
inform the health care provider correctly, while 
the health carer is committed to provide the best 
care possible for this patient. Lee and colleagues 
elegantly modelled this patient–provider relation-
ship as the foundation of care of the IPF patient.47 
Family caregivers should be involved from the 
onset of the disease and supported as they are the 
main support for the patient.5,48
Backing patients
Education is one of the crucial factors that 
empowers patients to make realistic choices and 
to play an active role in their care. The need for 
information is universal for patients with IPF and 
their families, and is iterated in all initiatives on 
identifying patient needs.5,18,19 Nowadays, many 
patients diagnosed with IPF and their relatives 
turn to online sources of health information. 
Fisher and colleagues showed that these online 
sources are frequently of poor quality, outdated, 
or not available in the patients’ native language.50 
In daily practise, clinicians and ILD specialist 
nurses play a central role in providing information 
and guiding patients to sources of information 
and support. Though information is such a cru-
cial factor, research on best practices of educating 
patients and partners is scarce. Some recent stud-
ies underlined that information should be gradu-
ally paced, and dyssynchrony between patient 
and partners in coping with the disease should be 
taken into account.5,50
Over the last several years, support groups for 
patients with IPF have expanded (http://www.pul-
monaryfibrosis.org/life-with-pf/support-groups). 
Support groups can decrease anxiety and depres-
sion, are helpful in educating patients and family 
caregivers, and can improve wellbeing.51 In oncol-
ogy, support groups have shown their merits in 
improving QOL.52,53 In IPF, unfortunately, only 
few studies have looked at the effect of support 
groups on the QOL of patients and family 
caregivers. Lindell and colleagues found that a 
6-week disease-management program, surpris-
ingly, decreased HRQOL and increased anxiety 
scores in IPF patients.54 Nevertheless, stress 
scores declined in their partners, and all partici-
pants found participation beneficial. Contrary to 
the study of Lindell and colleagues, unpublished 
data shows that a 3-week multidisciplinary patient 
and partner empowerment program for IPF 
(PPEPP) improved QOL.55 Patient advocacy 
groups can also play a role in providing informa-
tion, support and contact with other patients to 
share experiences. Besides this, patients should be 
advised on preventative measures. Although no 
convincing evidence exists on the benefits of vac-
cination in IPF, influenza and pneumococcal vac-
cinations are generally advised. If patients still 
smoke they should be strongly encouraged to quit 
smoking.
Trials remain crucial to advancing mechanistic 
insights and stimulating the development of bet-
ter therapies and intervention aimed at disease 
modification and improving HRQOL in IPF. A 
national survey of pulmonary fibrosis patients and 
family caregivers presented at the PFF Summit 
2015 showed that healthcare providers discussed 
the trials that were currently being conducted 
with only 55% of their patients (http://www.vid-
dler.com/v/197d1e49). Collaboration between 
patients, family caregivers and researchers is 
essential to advance care in IPF. Moreover, infor-
mation about ongoing research projects and reg-
istries should be made available to enable patients 
to make choices on possible participation in clini-
cal trials and registries.
Comorbidities and Comfort care
Adequate symptom relief is another crucial aspect 
in optimizing the QOL of patients and family car-
egivers.47 IPF is a disease with a high symptom 
burden for patients. Symptoms often escalate due 
to the progressive nature of IPF. In patients with 
IPF, comorbidities are frequent and may impor-
tantly contribute to symptom burden and QOL.56 
Identification and treatment of comorbidities 
may improve QOL and potentially influences 
prognosis.57 In the next section, we will review 
measures that may positively influence the most 
common symptoms patients with IPF experience; 
dyspnoea, cough, fatigue/deconditioning and 
depression/anxiety.8
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Dyspnoea. Dyspnoea is defined by the American 
Thoracic Society (ATS) as ‘a subjective experi-
ence of breathing discomfort that consists of 
qualitatively distinct sensations that vary in inten-
sity’.58 Almost all patients with IPF experience 
progressive dyspnoea, resulting in a major impact 
on their QOL; living with breathlessness impacts 
all aspects of daily life. Anxiety and avoidance of 
exertion lead to deterioration of functional 
impairment and social limitations.59 Dyspnoea 
and change in dyspnoea is also an independent 
predictor of survival.34,60,61 and has a complex 
pathophysiology. Possibly, numerous factors – 
such as mechanics related to the disease as well as 
psychological and neurological factors – play a 
role.58 Hence, it is useful to understand that 
hypoxemia does not always result in dyspnoea 
sensations in patients with IPF.
Data on managing IPF-related dyspnoea is scarce. 
It is important to first rule out comorbidities, such 
as pulmonary hypertension, cardiac disease, mus-
cle weakness, sleep disorders and psychosocial 
factors. Although antifibrotic therapies have a dis-
ease modifying effect and slow down decline in 
lung function, they do not reduce dyspnoea. 
There are a few small scale studies suggesting a 
beneficial effect of supplemental oxygen on dysp-
noea and exercise capacity in patients with IPF.62–
64 However, supplemental oxygen can also 
decrease patients’ QOL as it may restrict daily 
activities, can be expensive, and makes the disease 
more visible.65 Some patients regard the initiation 
of oxygen therapy as a negative landmark in their 
disease and, as such, often try to postpone start-
up. To increase acceptability, compliance and 
efficacy of supplemental oxygen, careful attention 
should be paid to the delivery system (e.g. pulse 
versus continuous, portable versus home-based).
Pulmonary rehabilitation is widely used to improve 
exercise capacity in patients with chronic disease. 
In IPF, pulmonary rehabilitation programmes 
have also been shown to improve dyspnoea, QOL, 
physical activity and body composition.66–68 
Unfortunately, improvements seem to decrease 
after finishing the program. Therefore, patients 
should be encouraged to attend a pulmonary 
rehabilitation maintenance programme, which 
may prolong the positive effect of participating.
There is a lack of good quality studies on the 
effect of opioids on dyspnoea symptoms in 
patients with IPF. The few existing studies show 
systemic opioids may have a favourable effect on 
patients’ experience of dyspnoea.69 As opioids are 
often seen as end-of-life care and may also have 
unfavourable side effects, such as constipation 
and sleepiness, conscientious explanation of their 
use and anticipation of side effects is recom-
mended. Colman and colleagues demonstrated in 
a small study that opioids can also be safely pre-
scribed to those patients with ILD on the waiting 
list for lung transplants.70 In a cohort of 38 
patients taking chronic opioids for their dysp-
noea, there was no respiratory depression and no 
clinically important opioid toxicity. Furthermore, 
they observed a trend toward increased exertion 
during exercise sessions with opioids versus pre-
opioids. ATS, for example, recommends opioids 
as a treatment option for patients with chronic 
respiratory disease, but also, advises discussing 
drug choice and dosing with patient and family 
caregivers beforehand.71
There are some indications that sildenafil might 
decrease dyspnoea and improve QOL in patients 
with IPF.72 However, debate on this exists and 
more research is needed.73 A simple intervention 
that might be beneficial for patients with IPF is 
the use of a handheld fan. Booth and colleagues 
studied the feasibility of this fan in patients with 
chronic refractory breathlessness and found a 
decrease of symptoms in half the patients.74
Cough. No reliable data are available on the 
prevalence of cough in IPF. Almost 80% of 
patients with IPF experience some chronic 
cough, but the number of patients with severe 
disabling cough may be lower.12,75 Nevertheless, 
cough is an invalidating symptom that can evoke 
spells of severe breathlessness and anxiety and 
may greatly impact patient’s social participa-
tion. Cough in IPF has been associated with dis-
ease progression.75 The exact underlying 
mechanism of cough in IPF patients is unknown, 
but is most probably ‘multifactorial’ and driven 
by mechanical, biochemical and neurosensory 
changes, with an important role for comorbidi-
ties as well.76–78
In the treatment of chronic cough in IPF, it is 
important to first exclude and treat underlying 
comorbidities. Frequent comorbidities are gastro-
esophageal reflux disease, obstructive sleep apnoea 
(OSA), chronic sinusitis, emphysema, lung can-
cer, infection and COPD associated chronic bron-
chitis. Angiotensin-converting-enzyme inhibitors 
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can also cause chronic cough directly after starting 
the medication, or even months later.79 IPF-
related cough is frequently refractory to antitus-
sive therapy, and the management of cough in 
IPF often consists of trying different treatment 
approaches and can thus be frustrating for both 
patients and clinicians. Low dose steroids are 
regularly tried for cough in IPF, though there is 
little data to support their effect.76 Considering 
the potential side effects and the fact that ster-
oids as primary treatment for IPF have been 
associated with worse outcome, risk and benefits 
should be carefully balanced. In other respira-
tory diseases, opioids have been shown to 
decrease cough, although such evidence is absent 
in IPF data. Thalidomide has been shown to 
decrease cough in a small 24-week double blind 
study.39 As only 20% of screened patients com-
pleted the study and thalidomide has a severe 
side effect profile, we would not recommend it 
as routine treatment. Recent findings suggest 
that the antifibrotic drug pirfenidone might have 
a positive effect on cough.80 As for nintedanib, 
its effect on cough is still unknown. While there 
are no convincing data on over-the-counter 
cough suppressants in IPF, some patients do 
report relief from these agents and the risks of 
trying them are negligible.
Fatigue and deconditioning. Many patients with 
IPF experience fatigue. The aetiology is multifac-
torial with factors such as deconditioning, reduc-
tion of skeletal muscle strength, cough, dyspnoea 
and hypoxemia likely to contribute. Additionally, 
comorbidities and psychological factors may play 
a role. Fatigue leads to fewer daily physical activi-
ties, resulting in a further decrease in exercise tol-
erance and muscle strength, which, in turn, 
increases the level of dependency and immobility, 
negatively affecting HRQOL and social participa-
tion. To objectively measure exercise capacity, a 
6-minute walk test or cycle ergometry can be 
done.81
In the treatment of fatigue and deconditioning, it 
is again important to rule out comorbidities such 
as cardiac disease, depression and OSA. Referral 
to pulmonary rehabilitation is, as for dyspnoea, 
recommended as treatment for fatigue and 
deconditioning in IPF patients. Treatment is dif-
ficult, as patients find it hard to exercise due to 
their fatigue and dyspnoea. A decrease in exer-
cise then provokes a downward spiral where 
muscle strength declines and leads to even less 
exercise.82 Early referral is advised, as patients 
probably benefit most when there they are still 
able to exercise at full power.83 In addition, oxy-
gen supplementation can be given when hypox-
emia limits exercise capacity; however, the exact 
benefits of oxygen therapy for fatigue in IPF 
patients are still unclear.64 The effects of phar-
macological therapy for fatigue symptoms in IPF 
patients is unknown.47
Anxiety and depression. In general, patients with 
chronic diseases are more susceptible to such 
symptoms as anxiety and depression. Also, many 
patients with IPF and their partners experience 
these symptoms.48,84 In ILDs, percentages vary 
from 7–49% for clinical meaningful depression, 
and 9–12% for clinical meaningful anxiety.4,43,85,86 
There is a known relationship between anxiety 
and breathlessness in other chronic diseases.87,88 
Breathlessness causes anxiety, as patients panic 
when they cannot breathe and fear the next attack. 
But anxiety can, on the other hand, increase the 
perception of breathlessness.59 It is stressful for 
family caregivers that they cannot help their loved 
ones during these attacks.22 Coughing can 
increase feelings of anxiety as it induces breath-
lessness as well. IPF patients also experience anxi-
ety and depression due to the side effects of 
medication and the uncertainty about the disease 
course in the context of a poor prognosis. Depres-
sion and anxiety are not only essential in predict-
ing the QOL for ILD patients, but can also 
aggravate breathlessness.42,84 Therefore, screening 
for depression and other underlying symptoms, 
that can increase psychological stress and may 
decrease the patients QOL, is needed.42
In the treatment of anxiety and depression, it is 
important to look at comorbidities such as OSA, 
fatigue and polypharmacy. Again, referral to pul-
monary rehabilitation can be beneficial.13,89 A 
valuable addition to pulmonary rehabilitation 
might be cognitive behavioural therapy (CBT).90 
CBT focuses on the relationship between 
thoughts, emotions, physical symptoms and 
behaviour, and enables people to cope with their 
negative thoughts.91 CBT has been shown to 
decrease anxiety and depression symptoms in 
patients with COPD and might be beneficial for 
all chronic physical diseases.42,91,92 In addition, 
ILD specialist nurses can play an important role 
in managing such symptoms as depression and 
anxiety. Since they are readily accessible and 
closely involved in the patient’s disease path, it is 
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easier for patients to talk to ILD specialists about 
their concerns and problems than doing so dur-
ing their short visits to the doctor. Support 
groups can also help patients with their emo-
tional struggles and are important for educating 
patients and their family caregivers.51 The effect 
of pharmacologic treatment for anxiety and 
depression, such as antidepressant medication, 
has not been studied in IPF; thus, the need to use 
such treatment should be considered thoroughly 
for each patient.
Disease-modifying treatment
The availability of two antifibrotic drugs with 
confirmed positive treatment effects has signifi-
cantly changed the course of the disease and the 
hopes for patients.11,12 Unfortunately, neither of 
these drugs cures IPF or completely halts disease 
progression, and lung transplantation remains 
the only curative treatment for the small minor-
ity of patients who are eligible for this major 
intervention. Although neither antifibrotic drug 
has convincingly demonstrated a positive effect 
on HRQOL, there is no evidence of negative 
reactions from side effects. It might well be that 
better tools are needed to detect changes in 
HRQOL. On the other hand, we should also 
consider the meaning of nonsignificant changes 
or stabilization of HRQOL for patients suffering 
from a disease that remains progressive. 
Furthermore, it might well be that disease modi-
fying agents do not necessarily improve a 
patient’s HRQOL. Since HRQOL is determined 
by many aspects of life and disease, it is evident 
that complementary treatment strategies are 
needed.
In the era before the availability of antifibrotic 
drugs, treatment goals gradually shifted during 
the course of the disease from more disease-cen-
tered management to more palliative measures.47 
Currently, this shift is less obvious as even when 
lung function declines, the effect of the antifi-
brotic drugs may still be present.93 Furthermore, 
these drugs may prevent the development of acute 
exacerbation12,94–96 and thereby protect the 
patient from a sudden decline in HRQOL or even 
death. In clinical practice, reassessing patients’ 
wishes and expectations, as well as incorporating 
the balance between efficacy and the burden of 
side effects, will guide decisions on discontinua-
tion of antifibrotic treatments.
End-of-life care
Despite the fact that IPF has a prognosis worse 
than most malignancies,97 end-of-life care is far 
less developed in this area of medicine than in 
oncology. Experiences from oncology have taught 
us that early palliative care improves the QOL 
and the mood of patients with metastatic lung 
cancer, and this, in turn, has resulted in less 
aggressive care and better survival.98 There are a 
few issues that complicate end-of-life care in IPF. 
The disease is rare and relatively unknown to 
patients and the community. In qualitative inter-
views, patients and their relatives frequently rated 
their situation worse than patients with cancer. 
They perceived that in cancer everybody under-
stands the seriousness of the disease and patients 
with cancer have ‘help coming from every direc-
tion’.17 Another factor is the variable course of 
disease in IPF, in which sudden acute exacerba-
tions can occur and prognosis is often unpredict-
able. Additionally, the timing of discussing 
end-of-life issues is difficult and should be tai-
lored to the patients’ needs and wishes. There can 
also be dyssynchrony between patient and part-
ners in wishing for information on this issue. 
Interactive questioning of patients in the 
Netherlands and Germany established that the 
majority of patients and partners prefer talking 
about the end-of-life early in the disease course, 
though we acknowledge that cultural differences 
may exist.48 It is useful, however, to realize that 
discussing end-of-life may be anxiety provoking 
and can have a negative impact on HRQOL.54 
Sampson and colleagues found that patients with 
IPF clearly understand their prognosis but strug-
gle to understand how their disease will pro-
gress.17 Explaining the course of the disease, what 
to expect in the last phase, and palliative options 
may enable patients and families to make deci-
sions in line with their values. In a recent study, 
only 13.7% of patients were referred to palliative 
care services,99 indicating that the use of palliative 
care teams is underutilized at the moment. 
Alternatively, Bajwah and colleagues showed that 
interdisciplinary community care conferences 
improved symptoms and QOL.100
Data from patients with other terminal diseases 
suggest that the majority of patients would prefer 
to die at home.101 Lindell and colleagues showed 
that in a US cohort of patients, more than half of 
the patients died in hospital, a third on the ICU, 
and the remaining patients died in a hospice.99 
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European studies showed that more patients died 
at home compared with the US study, but still a 
majority died in the hospital.102 Hospital admis-
sion for respiratory-related causes in IPF is asso-
ciated with high in-hospital mortality.103 The 
limited options and devastating outcomes of hos-
pital admission in the end-stage of the disease 
should be discussed with patients in an early 
phase to enable them to make decisions on limita-
tions of care and allow them to choose the place 
of dying. At the patient’s request – if this is legally 
possible in the country where the patient is seek-
ing treatment – different options of dying should 
also be discussed. Currently, worldwide, eutha-
nasia has been legalized under strict conditions in 
a few countries.104 In these countries, patients 
should be able to receive information on euthana-
sia. It is important to also discuss a ‘do not resus-
citate’ code and a ‘do not intubate’ code with 
patients and family to avoid medical futility or 
unwanted interventions.
Conclusion
In a relentless disease such as IPF, striving to 
optimize HRQOL should complement the 
endeavour to prolong life. As symptoms, percep-
tions and reactions interact, and may change over 
time, a synchronized comprehensive manage-
ment strategy is vital to match patients’ needs 
throughout the disease course. To do so, we pro-
pose the ABCDE of IPF care: Assess patients’ 
needs; give information and support to Back 
patients; deliver Comfort care by focusing on 
treating symptoms, also taking into account 
Comorbidities; strive to prolong life by Disease 
modification; and help and prepare patient and 
family for the End-of-life. To optimize QOL for 
patients with IPF, we need to provide patient-
centred care that is comprehensive and not mainly 
focused on disease modification therapies.
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